Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer

Focusing Decision-Making & Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCПодробнее

Focusing Decision-Making & Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC

Empowering Changes and Revolutionizing Treatment and Equity in Breast CancerПодробнее

Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer

HR+, HER2 , High Risk EBC A Practical Roadmap for CDK4 6 Inhibition in the Adjuvant SettingПодробнее

HR+, HER2 , High Risk EBC A Practical Roadmap for CDK4 6 Inhibition in the Adjuvant Setting

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

Highlights from SABCS 2020: New data on CDK4/6 inhibitors, omitting chemotherapy and radiotherapyПодробнее

Highlights from SABCS 2020: New data on CDK4/6 inhibitors, omitting chemotherapy and radiotherapy

New Advances and Opportunities for Improvement in HR+/HER2- Early Breast CancerПодробнее

New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer

2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic TherapyПодробнее

2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic Therapy

ESMO Daily Reporter Talk: The role of CDK4/6 inhibitors in the early stage of #breastcancer.Подробнее

ESMO Daily Reporter Talk: The role of CDK4/6 inhibitors in the early stage of #breastcancer.